PR Web (press release) | ECOG-ACRIN Opens Clinical Trial Investigating Ibrutinib-Rituximab ... PR Web (press release) Ibrutinib, a small molecule inhibitor of Bruton's tyrosine kinase, will be investigated in combination with rituximab by the ECOG-ACRIN Cancer Research Group in its latest clinical trial, E1912. Share on Twitter Share on Facebook Share on Google+ Share ... |
